AnaptysBio announces intent to separate into two publicly traded companies

AnaptysBio (ANAB) announced that its board approved plans to explore separating its business into two independent, publicly traded companies. Referred to as “Royalty Management Co” and as “Biopharma Co”, the two companies’ different business models “enable investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company.” Upon completion, Royalty Management Co will hold and continue to manage the rights to the potential substantial Jemperli royalties from GSK and imsidolimab milestones and royalties from Vanda with a focus on protecting and returning value of the royalties to its shareholders. Upon completion, Biopharma Co will be a clinical-stage biotechnology company focused on the development and potential commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101.